"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
| Descriptor ID |
D004317
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
|
| Concept/Terms |
Adriblastin- Adriblastin
- Adriblastine
- Adriblastina
- Adriablastine
- Adriablastin
DOXO-cell- DOXO-cell
- DOXO cell
- Urokit Doxo-cell
- Urokit Doxo cell
|
Below are MeSH descriptors whose meaning is more general than "Doxorubicin".
Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".
This graph shows the total number of publications written about "Doxorubicin" by people in this website by year, and whether "Doxorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 3 | 4 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 3 | 4 |
| 1999 | 1 | 1 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 4 | 5 |
| 2003 | 2 | 5 | 7 |
| 2004 | 2 | 4 | 6 |
| 2005 | 0 | 5 | 5 |
| 2006 | 2 | 3 | 5 |
| 2007 | 1 | 4 | 5 |
| 2008 | 2 | 7 | 9 |
| 2009 | 2 | 8 | 10 |
| 2010 | 0 | 6 | 6 |
| 2011 | 1 | 9 | 10 |
| 2012 | 2 | 3 | 5 |
| 2013 | 0 | 8 | 8 |
| 2014 | 3 | 11 | 14 |
| 2015 | 4 | 9 | 13 |
| 2016 | 2 | 3 | 5 |
| 2017 | 3 | 5 | 8 |
| 2018 | 2 | 11 | 13 |
| 2019 | 7 | 4 | 11 |
| 2020 | 3 | 8 | 11 |
| 2021 | 1 | 5 | 6 |
| 2022 | 0 | 6 | 6 |
| 2023 | 1 | 5 | 6 |
| 2024 | 3 | 4 | 7 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
Comparison of the Cytotoxicity, Internalization and Anti-Cancer Drug Delivery Efficacy of Nature Killer Cell Derived Nanovesicles and Extracellular Vesicles. Int J Nanomedicine. 2025; 20:10683-10700.
-
Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study. Breast Cancer Res Treat. 2025 Nov; 214(1):69-77.
-
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium. Blood Adv. 2025 Mar 11; 9(5):1013-1023.
-
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma. Blood. 2025 Jan 16; 145(3):290-299.
-
Treatment of focal anaplastic Wilms tumor: A report from the Children's Oncology Group AREN0321 and AREN03B2 studies. Cancer. 2025 Jan 15; 131(2):e35713.
-
Diffuse Large B-Cell Lymphoma/High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Study of 60 Cases. Mod Pathol. 2025 May; 38(5):100710.
-
Inosine monophosphate dehydrogenase 2 (IMPDH2) modulates response to therapy and chemo-resistance in triple negative breast cancer. Sci Rep. 2025 01 07; 15(1):1061.
-
Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Am J Hematol. 2025 Mar; 100(3):402-407.
-
Rhabdoid Tumor of the Kidney and Soft Tissues: Results from National Wilms Tumor Study-5 and Children's Oncology Group Study AREN0321. Pediatr Blood Cancer. 2025 Mar; 72(3):e31490.
-
Self-targeted smart polyester nanoparticles for simultaneous Delivery of photothermal and chemotherapeutic agents for efficient treatment of HCC. Biomater Sci. 2024 Dec 03; 12(24):6368-6381.